CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM Arzneimittel GmbH Announces Offering

Greifswald, Germany – Cheplapharm Arzneimittel GmbH (“we, “us”, or the “Company”) announces that it has launched an offering of €1,000,000,000 (equivalent) aggregate principal amount of senior secured notes due 2028 (the “Notes”). The Notes comprise a euro-denominated tranche and U.S. dollar denominated tranche and are being offered only to qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and to non-U.S. persons outside the United States in offshore transactions in reliance on Regulation S under the Securities Act. The interest rate, offering price and certain other terms will be determined at the time of pricing of the Notes, subject to market conditions.

The Company intends to use the proceeds from the offering of the Notes, together with the proceeds of a drawdown under its revolving credit facility and cash on hand to (i) pay the purchase price for three portfolios of pharmaceutical products it agreed to acquire in between June and September 2020 and the acquisition of worldwide marketing authorizations for Rivotril® as well as (ii) costs and expenses related to the foregoing.


Investor Relations topics

Back to top expand_less